@article{fdi:010072862,
  title = {{B}edaquiline resistance : its emergence, mechanism, and prevention},
  author = {{N}guyen, {T}. {V}. {A}. and {A}nthony, {R}. {M}. and {B}anuls, {A}nne-{L}aure and {N}guyen, {T}. {V}. {A}. and {V}u, {D}. {H}. and {A}lffenaar, {J}. {W}. {C}.},
  editor = {},
  language = {{ENG}},
  abstract = {{B}edaquiline, a new antituberculosis drug, has already been used in >50 countries. {T}he emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. {T}his article aims to review currently identified mechanisms of resistance and the emergence of bedaquiline resistance, and discuss strategies to delay the resistance acquisition. {I}n vitro and clinical studies as well as reports from compassionate use have identified the threat of bedaquiline resistance and cross-resistance with clofazimine, emphasizing the crucial need for the systematic surveillance of resistance. {C}urrently known mechanisms of resistance include mutations within the atp{E}, {R}v0678, and pep{Q} genes. {T}he development of standardized drug susceptibility testing ({DST}) for bedaquiline is urgently needed. {U}nderstanding any target and non-target-based mechanisms is essential to minimize resistance development and treatment failure and help to develop appropriate {DST} for bedaquiline and genetic-based resistance screening.},
  keywords = {bedaquiline ; resistance ; cross-resistance ; mechanisms ; drug ; susceptibility testing},
  booktitle = {},
  journal = {{C}linical {I}nfectious {D}iseases},
  volume = {66},
  numero = {10},
  pages = {1625--1630},
  ISSN = {1058-4838},
  year = {2018},
  DOI = {10.1093/cid/cix992},
  URL = {https://www.documentation.ird.fr/hor/fdi:010072862},
}